Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Schering’s SAPHRIS Meets Primary Endpoint in Long-Term Extension Study

By Pharmaceutical Processing | July 24, 2009

Schering-PloughCorporation has announced that its investigational agentSAPHRIS(R) (asenapine) met the primary endpoint over one year of treatment inan extension study in patients with predominant, persistent negative symptomsof schizophrenia. Negative symptoms of schizophrenia include apathy, lack of emotion andpoor social functioning, among others. In the study, these symptoms wereassessed using the validated 16-item Negative Symptom Assessment scale(NSA-16). “These symptoms are among the most difficult to treat in the schizophreniaspectrum,” said Armin Szegedi, M.D., Ph.D., vice president, global clinicalresearch, central nervous system, Schering-Plough Research Institute. “Fewstudies with the antipsychotics currently available on the market have beendesigned specifically to evaluate long-term effects on predominant, persistentnegative symptoms. The results from this large clinical study program willprovide new insights into potential treatment of these symptoms.” In the study, SAPHRIS was significantly more effective than olanzapine inthe reduction of negative symptoms as measured by change from baseline to Day365 in the NSA-16 total score, the primary endpoint of the study. By using amixed model for repeated measures (MMRM), least square mean changes in theNSA-16 total score were -15.8 for SAPHRIS vs. -11.0 for olanzapine (P0.015).Full results of the trial, including efficacy, safety and tolerability data,will be submitted for presentation at a medical meeting at a later date. These results follow those of a previously reported clinical trial in thispatient population using the same study design and protocol in which bothasenapine and olanzapine reduced negative symptoms after one year oftreatment, but the difference between the two was not statisticallysignificant. Additionally, a preliminary pooled analysis of the combined data for thesetwo identically designed studies showed a statistically significant treatmenteffect in favor of asenapine after one year of treatment. These large Phase III studies were conducted following a previous Phase IIstudy where favorable data on negative symptoms were observed for asenapine.About the study

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE